Orals

Telmisartan

Name: Telmisartan
Brand: Quanta Pharmaceuticals

An angiotensin II receptor blocker studied for blood pressure management and cardiovascular risk research.

Telmisartan is an angiotensin II receptor blocker (ARB) studied extensively for its role in blood pressure regulation and cardiovascular risk research. This formulation supplies 60 tablets of 40mg per tub. Chemically classified as C33H30N4O3, Telmisartan selectively blocks the AT1 receptor, preventing angiotensin II from exerting its vasoconstrictive and aldosterone-stimulating effects. It is also notable in the research literature for partial PPARγ agonism — structural studies show its benzimidazole ring binds PPARγ in a way that only weakly stabilises the receptor's activation helix, giving roughly 25-30% of the activity of a full PPARγ agonist. This partial activation is studied for potential metabolic benefits without the fluid-retention and weight-gain liabilities seen with full PPARγ agonists (thiazolidinediones). With a half-life of approximately 24 hours — the longest of any ARB in its class — Telmisartan supports stable once-daily dosing and consistent receptor blockade across a full day.

Verify a product

Specifications

Tablets

Dose Per Tablet

40mg

Half-Life

24 hours

Administration

Oral

Chemical Structure

C33H30N4O3

Research Benefits

Blood Pressure Regulation — Studied for blocking AT1 receptors to reduce angiotensin II-driven vasoconstriction.
Cardiovascular Risk Research — Investigated for its broader role in cardiovascular protection protocols.
Partial PPARγ Activity — Structural research shows it activates PPARγ at roughly 25-30% of a full agonist's strength, distinguishing it from other ARBs without the side-effect profile of full agonists.
Long Duration of Action — A 24-hour half-life among the longest in its class supports stable once-daily dosing.
Renal and Vascular Research — Frequently studied for downstream effects on vascular and renal function markers.

How It Works

Telmisartan selectively antagonises the angiotensin II type 1 (AT1) receptor, blocking the vasoconstrictive, aldosterone-stimulating, and sympathetic-activating effects that angiotensin II would otherwise produce. This receptor blockade is the primary mechanism studied for its blood pressure-lowering effect.

Uniquely among ARBs, Telmisartan also exhibits partial agonism at PPARγ, a nuclear receptor involved in metabolic regulation, a property that has drawn separate research interest beyond its cardiovascular applications. Its 24-hour half-life, one of the longest in its class, supports stable receptor blockade from a single daily dose.

⚠ For Research Use Only

This product is supplied strictly for in-vitro laboratory and preclinical research use. It is not a drug, food, dietary supplement, or cosmetic, and is not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease. Telmisartan must be handled only by qualified individuals trained in proper laboratory safety procedures.

By purchasing, the buyer confirms this product is being acquired for legitimate research purposes and assumes full responsibility for its handling, storage, and use in compliance with all applicable local, national, and international laws.